Hosted on MSN10mon
New bowel tumor drug helped cure cancer in 100% of cases
We look forward to evaluating dostarlimab-gxly in certain colorectal cancers in our ongoing AZUR-1 and AZUR-2 registrational studies." GSK said the patients in the study did not experience adverse ...
Medical miracle? Experimental drug wipes out colorectal cancer completely in trial
In what can be termed a never-seen-before medical miracle, a small group of people with colorectal cancer achieved 100% ...
Nasdaq8d
LIXTE Biotechnology Updates Progress On LB-100 In Ovarian And Colorectal Cancer Trials
dostarlimab-gxly. In addition, a new trial is being conducted at the Netherlands Cancer Institute for MSI Low metastatic colorectal cancer, supported by Roche. LIXTE also received a significant ...
Yahoo Finance9d
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
Our colorectal trial, supported by F ... in a Phase 1b/2 trial combining LIXTE's LB-100 with GSK's immunotherapy, dostarlimab-gxly, targeting ovarian clear cell carcinoma. Dosing of the first ...
Nasdaq1mon
LIXTE Biotechnology Teams Up with Lurie Cancer Center to Initiate Clinical Trial of LB-100 and GSK’s Dostarlimab for Ovarian Clear Cell Cancer
Lurie Cancer Center initiates trial combining LIXTE's LB-100 and GSK's Dostarlimab for ovarian clear cell cancer treatment. LIXTE Biotechnology Holdings, Inc. has announced that the Robert H.
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal ...